Stephen Shumack

Summary

Country: Australia

Publications

  1. ncbi Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens
    Stephen Shumack
    St George Dermatology and Skin Cancer Center, Level 3, 22 Belgrave St, Kogarah, Australia 2217
    Arch Dermatol 138:1165-71. 2002
  2. ncbi Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]
    Jean Paul Ortonne
    Serono International S A Geneva, Switzerland
    BMC Dermatol 5:13. 2005

Collaborators

  • Steven Kossard
  • Jean Paul Ortonne
  • Neil Shear
  • Eric Henninger
  • Jean-Paul Ortonne

Detail Information

Publications2

  1. ncbi Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens
    Stephen Shumack
    St George Dermatology and Skin Cancer Center, Level 3, 22 Belgrave St, Kogarah, Australia 2217
    Arch Dermatol 138:1165-71. 2002
    ..To establish a safe and efficacious dosing regimen for the treatment of primary nodular basal cell carcinoma (BCC) using 5% imiquimod cream...
  2. ncbi Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]
    Jean Paul Ortonne
    Serono International S A Geneva, Switzerland
    BMC Dermatol 5:13. 2005
    ..Efalizumab has demonstrated safety and efficacy in several clinical trials, and improves patients' quality of life...